secwatch.observer — SEC 8-K summary
======================================

Issuer:     ILLUMINA, INC. (ILMN)
CIK:        0001110803
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001193125-25-144290
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Illumina to acquire SomaLogic for $350M cash plus up to $75M milestones
-----------------------------------------------------------------------

- Illumina will acquire SomaLogic's aptamer-based proteomics business from Standard BioTools for $350M cash at closing, plus up to $75M in milestones and royalties.
- Transaction includes SomaLogic's SomaScan assay, CLIA/CAP lab in Boulder, CO, and ~250 employees; builds on co-development since 2021.
- Illumina expects the business to become profitable on a non-GAAP basis in 2027, with operating margins in line with Illumina by 2028.
- Closing expected in first half of 2026, subject to HSR and other customary conditions; termination fee of $14.5M under certain circumstances.
- Illumina Protein Prep (SomaScan on NGS) already has ~40 early-access customers, full availability in Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1110803/000119312525144290/0001193125-25-144290-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1110803/000119312525144290/d66921d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-144290

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer